Elevation Oncology Stock Insider Trading

Healthcare > Biotechnology

Buy ELEV

*Your capital is at risk

$0.365

+0 (+0%)

At Close: Oct 22, 2025

Elevation Oncology Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -98.01. In total, the insiders bought 543.5K and sold 3.3M ELEV shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-98.01
● Buy	543.5K shares
● Sell	3.3M shares
29% Buy Activity Weak Positive Correlation
Sell Signal Medium Confidence Jul 23, 2025 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -98.01. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Sandler Alan B. Director	Director	55 000 Value: $242.6K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Sandler Alan B. Director	Director	35 000 Value: $117.3K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Sandler Alan B. Director	Director	35 000 Value: $10.7K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Mootz Darcy Director	Director	55 000 Value: $150.7K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Mootz Darcy Director	Director	35 000 Value: $117.3K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Mootz Darcy Director	Director	35 000 Value: $10.7K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Elms Steve Director	Director	31 238 Value: $499.8K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Elms Steve Director	Director	15 619 Value: $20.5K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Elms Steve Director	Director	31 238 Value: $45.9K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Elms Steve Director	Director	35 000 Value: $117.3K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Elms Steve Director	Director	35 000 Value: $10.7K
Jul 23, 2025 Sell	Common Stock U-Tender	Clackson Timothy P Director	Director	47 330 Value: $17.0K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Clackson Timothy P Director	Director	15 619 Value: $20.5K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Clackson Timothy P Director	Director	31 238 Value: $45.9K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Clackson Timothy P Director	Director	35 000 Value: $117.3K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Clackson Timothy P Director	Director	35 000 Value: $10.7K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Cherrington Julie M Director	Director	55 000 Value: $242.6K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Cherrington Julie M Director	Director	35 000 Value: $117.3K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Cherrington Julie M Director	Director	35 000 Value: $10.7K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Carruthers R Michael Director	Director	47 330 Value: $146.2K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Carruthers R Michael Director	Director	15 619 Value: $20.5K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Carruthers R Michael Director	Director	31 238 Value: $45.9K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Carruthers R Michael Director	Director	35 000 Value: $117.3K
Jul 23, 2025 Sell	Stock Option (Right to Buy) D-Return	Carruthers R Michael Director	Director	35 000 Value: $10.7K
Jul 23, 2025 Sell	Common Stock U-Tender	Furlong Tammy Chief Financial Officer	C-Suite Officer	37 957 Value: $13.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ELEVATION ONCOLOGY, INC.

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is bas...

Read Full Profile Here